New treatment options bring hope to the many people with obesity who struggle with this disease and are seeking better options for weight management. The approval was based on results from the phase III SURMOUNT-1 and SURMOUNT-2 trials
Weekly exposure (57 days/week) Weekly Exposure From the 1:1 Pre-blended Vial Daily blend dose 0.5 mg/day Weekly total blend 2.53.5 mg Weekly BPC-157 1.251.75 mg Weekly TB-500 1.251.75 mg Daily blend dose 1.0 mg/day Weekly total blend 5.07.0 mg Weekly BPC-157 2.53.5 mg Weekly TB-500 2.53.5 mg Daily blend dose 1.5 mg/day Weekly total blend 7.510.5 mg Weekly BPC-157 3.755.25 mg Weekly TB-500 3.755.25 mg Daily blend dose 2.0 mg/day Weekly total blend 10.014.0 mg Weekly BPC-157 5.07.0 mg Weekly TB-500 5.07.0 mg Use this to compare a blend schedule against the separate-vial weekly totals in the next tab
Remember that perimenopausal weight management is a marathon, not a sprint, and multiple strategies may be needed to achieve sustainable results whilst supporting overall health during this transitional phase
Because of the various barriers to affordable coverage, some businesses are instead considering pointing employees toward the cash-pay option accessing a significantly reduced price tag by paying out of pocket rather than going through insurance
Data show that both FDA-approved drugs, Wegovy from Novo Nordisk and Zepbound from Eli Lilly, are highly effective
The good news is that these effects are manageable with proper titration and awareness
